Baker BROS. Advisors LP Invests $3.57 Million in 4D Molecular Therapeutics, Inc. $FDMT

Baker BROS. Advisors LP acquired a new stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 475,737 shares of the company’s stock, valued at approximately $3,568,000. Baker BROS. Advisors LP owned 0.83% of 4D Molecular Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in FDMT. State Street Corp boosted its position in 4D Molecular Therapeutics by 197.5% during the 4th quarter. State Street Corp now owns 2,688,880 shares of the company’s stock valued at $20,167,000 after purchasing an additional 1,785,106 shares during the period. RA Capital Management L.P. boosted its position in 4D Molecular Therapeutics by 23.9% during the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after purchasing an additional 1,090,000 shares during the period. Adage Capital Partners GP L.L.C. boosted its position in 4D Molecular Therapeutics by 605.8% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,235,156 shares of the company’s stock valued at $9,264,000 after purchasing an additional 1,060,156 shares during the period. Armistice Capital LLC boosted its position in 4D Molecular Therapeutics by 76.6% during the 4th quarter. Armistice Capital LLC now owns 1,936,000 shares of the company’s stock valued at $14,520,000 after purchasing an additional 840,000 shares during the period. Finally, Federated Hermes Inc. boosted its position in 4D Molecular Therapeutics by 33.4% during the 2nd quarter. Federated Hermes Inc. now owns 1,667,338 shares of the company’s stock valued at $6,186,000 after purchasing an additional 417,157 shares during the period. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Performance

Shares of FDMT stock opened at $9.42 on Thursday. 4D Molecular Therapeutics, Inc. has a 1 year low of $3.68 and a 1 year high of $12.34. The stock has a fifty day moving average of $9.44 and a two-hundred day moving average of $9.14. The firm has a market capitalization of $492.48 million, a PE ratio of -3.67 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The business had revenue of $3.05 million for the quarter, compared to analyst estimates of $2.59 million. Equities research analysts predict that 4D Molecular Therapeutics, Inc. will post -3.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

FDMT has been the subject of a number of analyst reports. Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Chardan Capital restated a “buy” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, March 19th. HC Wainwright restated a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Friday, March 20th. Jefferies Financial Group restated a “buy” rating and set a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. Finally, Royal Bank Of Canada boosted their price objective on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.88.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.